Darunavir
The Chinese authorities have indicated that Darunavir against 2019-nCoV
may be successful. In vitro cell studies have shown that
Darunavir can effectively inhibit replication of the new strain, at a
concentration of 300 micromolar, according to preliminary research
Darunavir, in conjunction with cobicistat, will be used in patients with
COVID-19 pneumonia in trial number NCT04252274 (50). Such a mixture is
currently approved by the United States Food and Drug Administration
(FDA) in AIDS treatment. Darunavir is another HIV protease inhibitor and
cobicistat, like ritonavir, is a booster to enhance the pharmacokinetics
and pharmacodynamics of darunavir by inhibiting cytochrome P450 (CYP3A)
[53] [54]. Due to in vitro evidence that supports its ability to
fight this infection, Darunavir is being studied as a potential cure for
SARS-CoV-2, the coronavirus responsible for COVID-19 [52]. Clinical
trials are under progress and are scheduled to end in August 2020.
Several registered clinical trials are currently being conducted
globally to evaluate the efficacy of the drugs against COVID-19
(Table-1)